Inherited mutations typical in triple-negative breast cancer

This article originally appeared here.
Inherited Mutations Common in Triple-Negative Breast Cancer
Inherited Mutations Common in Triple-Negative Breast Cancer

(HealthDay News) -- Almost 15 percent of patients with triple-negative breast cancer unselected for family history have deleterious mutations in breast cancer susceptibility genes, according to a study published online Dec. 1 in the Journal of Clinical Oncology.

Fergus J. Couch, Ph.D., from the Mayo Clinic in Rochester, Minn., and colleagues recruited 1,824 patients with triple-negative breast cancer, unselected for family history of breast or ovarian cancer, through 12 studies. Germline DNA was sequenced to identify mutations in 17 predisposition genes, including BRCA1 and BRCA2.

The researchers found that 14.6 percent of all patients had deleterious mutations. Of these, 11.2 percent had mutations in BRCA1 and BRCA2 (8.5 and 2.7 percent, respectively). In 3.7 percent of patients, they detected deleterious mutations in 15 other predisposition genes, mostly in genes involved in homologous recombination, including PALB2, BARD1, RAD51D, RAD51C, and BRIP1. Compared with those without mutations, patients with mutations were diagnosed at an earlier age and had higher-grade tumors.

"Mutation prevalence estimates suggest that patients with triple-negative breast cancer, regardless of age at diagnosis or family history of cancer, should be considered for germline genetic testing of BRCA1 and BRCA2," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry.

Abstract
Full Text (subscription or payment may be required)

Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs